PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lubiprostone→

Lubiprostone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
333963-40-9
PubChem CID
157920
Molecular formula
C20H32F2O5
Molecular weight
390.5 g/mol
Drug class
Chloride Channel Activator
Mechanism of action
Chloride Channel Activators [MoA]
Indications / reported uses
  • Constipation
  • Irritable Bowel Syndrome
  • chronic idiopathic constipation (CIC) in adults
  • opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e
  • irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old

Sources: FDA product labels (openFDA) · FDA product information

Identification source: PubChem record (CID 157920). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Lubiprostone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lubiprostone Permitted Daily Exposure (PDE) report (the Lubiprostone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lubiprostone Occupational Exposure Limit (OEL) report (the Lubiprostone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.